Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors

Fineline Cube May 9, 2026
Company Drug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Fineline Cube May 9, 2026
Company Medical Device

Zylox-Tonbridge Secures NMPA Approval for Advanced Flow Diverter Targeting Intracranial Aneurysms

Fineline Cube Mar 26, 2024

Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices,...

Company Deals

Novo Nordisk Expands Benzalkonium Chloride Distribution with Actylis Across Europe

Fineline Cube Mar 26, 2024

Denmark’s Novo Nordisk (CPH: NOVO-B), through its Pharmatech division, announced a partnership this week with...

Company

WuXi XDC Reports 114.4% YOY Revenue Growth in 2023, Driven by ADC CRDMO Business

Fineline Cube Mar 26, 2024

WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi STA,...

Company Drug

Jiangsu Hengrui’s Generic Version of Tepadina Approved for Transplantation Conditioning in China

Fineline Cube Mar 26, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

MSD’s Phase III Trial of Keytruda Plus Lynparza Misses Primary Endpoints in NSCLC

Fineline Cube Mar 25, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an unfavorable outcome for a Phase...

Company

Sandoz Expands Antibiotics Production with New Austrian Factory

Fineline Cube Mar 25, 2024

Sandoz (OTCMKTS: SDZNY), a Swiss pharmaceutical company, has announced the opening of a new antibiotics...

Company Drug

Shanghai Institute’s Biosimilar Rituximab Approved by NMPA for Lymphoma Treatments

Fineline Cube Mar 25, 2024

Shanghai Institute of Biological Products Co., Ltd has announced that its biosimilar version of Roche/Genentech’s...

Company Drug

EMA Panel Backs Novartis’s Fabhalta for PNH Treatment, Awaits EC Decision

Fineline Cube Mar 25, 2024

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company

Sumitomo Pharma’s China CEO Highlights Strategic Importance of Local Market

Fineline Cube Mar 25, 2024

Yoshitaka Koketsu, CEO of Sumitomo Pharma (TYO: 4506) (China) Co., Ltd, the Chinese subsidiary of...

Company

Roche Invests EUR 90 Million in New Gene Therapy Center in Germany

Fineline Cube Mar 25, 2024

Swiss pharmaceutical giant Roche (SWX: RO) has inaugurated a new gene therapy development center in...

Company Drug

Sanofi Projects EUR 13 Billion in Dupixent Sales for 2024 Despite Q1 Challenges

Fineline Cube Mar 25, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its guidance for the first...

Company Drug

FibroGen’s Roxadustat Approved in Macau for Chronic Kidney Disease-Related Anemia

Fineline Cube Mar 25, 2024

FibroGen Inc. (NASDAQ: FGEN), a biopharmaceutical company based in the US, has announced that it...

Policy / Regulatory

China’s Commerce Minister Meets with Global Pharma Leaders to Discuss Innovation Cooperation

Fineline Cube Mar 25, 2024

China’s Minister of Commerce, Wang Wentao, convened a high-level meeting with top executives from the...

Company Drug

Yifan Pharmaceutical’s F-627 Approved by European Commission for Marketing in EU

Fineline Cube Mar 25, 2024

Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that its subsidiary...

Company Deals

OBiO Technology Partners with Saierxin Bio to Support Treg Cell Therapy Development

Fineline Cube Mar 25, 2024

OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a Chinese Contract Research Organization (CRO) specializing in...

Company Drug

Grand Pharma Receives NMPA Approval for Global Phase III Study of RDC ITM-11 in GEP-NETs

Fineline Cube Mar 25, 2024

Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...

Company Medical Device

Jenscare Scientific Completes Enrollment in Clinical Study for Mitral Valve Repair System

Fineline Cube Mar 25, 2024

Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer headquartered in...

Company Deals Digital

Zhejiang Dian Diagnostics Partners with Haihe Laboratory to Advance Hematology Diagnostics

Fineline Cube Mar 25, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a company based in China, has entered into...

Company Deals

Golden Leaf Med Tec Secures Series D Funding to Advance Hypertension and Diabetes Treatments

Fineline Cube Mar 25, 2024

Shanghai Golden Leaf Med Tec Co., Ltd, a specialist in interventional treatments based in China,...

Company Deals Drug

Joincare Pharmaceuticals Secures Rights to Bayer’s Respiratory Drug in China

Fineline Cube Mar 25, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a...

Posts pagination

1 … 381 382 383 … 662

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors
  • Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda
  • Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China
  • Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline
  • Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors

Company Drug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Company Drug

Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China

Company Drug

Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.